Company Overview of Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FP-1039/GSK3052230, a protein therapeutic, which is in Phase 1b clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, a Phase 1 clinical trial stage antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumo...
Two Corporate Drive
South San Francisco, CA 94080
Founded in 2001
Key Executives for Five Prime Therapeutics, Inc.
Total Annual Compensation: $525.0K
Chief Business Officer
Total Annual Compensation: $362.8K
Chief Medical Officer and Senior Vice President
Total Annual Compensation: $350.0K
Senior Vice President
Total Annual Compensation: $311.9K
Compensation as of Fiscal Year 2013.
Five Prime Therapeutics, Inc. Key Developments
Five Prime Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 01:30 PM
May 21 14
Five Prime Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 01:30 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Julie Hambleton, Chief Medical Officer and Senior Vice President, Lewis T. Williams, Founder, Chief Executive Officer, President and Director.
Five Prime Therapeutics, Inc. Reports Financial Results for the First Quarter Ended March 31, 2014; Provides Cash Flow Guidance for the Full Year of 2014
May 8 14
Five Prime Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2014. For the quarter, the company reported collaboration revenue increased 17% to $3.5 million from $3.0 million in the first quarter of 2013. This increase was primarily attributed to revenue earned under the fibrosis and CNS collaboration with UCB initiated in March 2013. Loss from operations was $8,660,000 compared to $7,347,000 last year. Net loss was $8.6 million, or $0.46 per basic and diluted share, compared to a net loss of $7.0 million, or $5.73 per basic and diluted share, for the first quarter of 2013. This increase in net loss was primarily due to the advancement of FPA144 towards a fourth quarter 2014 IND submission and public company-related expenses.
The company continues to expect full-year 2014 net cash used in operating activities to be less than $30 million.
Five Prime Therapeutics, Inc. to Report Q1, 2014 Results on May 08, 2014
May 1 14
Five Prime Therapeutics, Inc. announced that they will report Q1, 2014 results After-Market on May 08, 2014
Similar Private Companies By Industry
Recent Private Companies Transactions
March 19, 2014